| Literature DB >> 31198783 |
Wurong Li1,2,3, Meijuan Jiang3, Dongmei Xu3, Cheng Kou3, Lei Zhang3, Junhua Gao3, Kaiyu Qin3, Wenqing Wu3, Xinghu Zhang1,2.
Abstract
A retrospective study was performed to compare the differences in clinical and laboratory features of asymptomatic neurosyphilis (ANS) and symptomatic neurosyphilis (SNS). A total of 264 HIV-negative inpatients with neurosyphilis were enrolled from Beijing Ditan Hospital and Beijing Tiantan Hospital between January 2014 and May 2018, including 110 SNS and 154 ANS. The SNS group had more patients in males, older median age and without antisyphilis treatment than ANS group (P<0.001, P<0.001, and P<0.001, respectively). The laboratory findings showed that the SNS group had higher pretreatment serum rapid plasma regain (RPR) titer, current serum RPR titer, cerebrospinal fluid (CSF) white blood cell (WBC) counts, CSF protein concentrations, and higher positive CSF RPR rate than those in the ANS group (P=0.011, P<0.001, P<0.001, P<0.001, and P<0.001, respectively). The multivariate logistic regression analysis revealed that male (OR=2.833, P=0.009), age≥45 years (OR=3.611, P=0.001), without antisyphilis treatment (OR=0.247, P<0.001), higher current serum RPR titer (OR=1.373, P=0.022), positive CSF RPR (OR=4.616, P<0.001), and higher CSF protein concentration (OR=1.017, P=0.026) were independent risk predictors for SNS. Therefore, clinical and laboratory features between SNS and ANS are quietly different. Male gender, age≥45 years, and lack of antisyphilis treatment are risk factors for SNS. The elevated level of serum RPR titer, CSF protein concentration, and CSF RPR titer may indicate the development of neurosyphilis and the aggravation of neurological symptoms.Entities:
Mesh:
Year: 2019 PMID: 31198783 PMCID: PMC6526518 DOI: 10.1155/2019/2426313
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Patient Demographics and Baseline Characteristics (N = 264).
| Characteristic | SNS (110) | ANS (154) | P value |
|---|---|---|---|
| Sex (male: female) | 88:22 | 72:82 | P<0.001 |
| Age (years), median year (IQR) | 50 (44, 58) | 39 (30, 52) | P<0.001 |
| ≤ 30 | 5, 4.5% | 42, 27.3% | NA |
| 31~40 | 13, 11.8% | 37, 24.0% | NA |
| 41~50 | 38, 34.5% | 31, 20.1% | NA |
| 51~60 | 34, 30.9% | 33, 21.4% | NA |
| ≥ 61 | 20, 18.2% | 11, 7.1% | NA |
| Treatment history (yes: no) | 43:67 | 99:55 | P<0.001 |
| Pretreatment serum RPR titer, median (IQR) | 1:32 (1:16, 1:64) | 1:32 (1:8, 1:64) | P=0.011 |
| 1:1 (n, %) | 1, 0.9% | 0, 0% | NA |
| 1:2 (n, %) | 0, 0% | 4, 2.6% | NA |
| 1:4 (n, %) | 2, 1.8% | 10, 6.5% | NA |
| 1:8 (n, %) | 14, 12.7% | 24, 15.6% | NA |
| 1:16 (n, %) | 13, 11.8% | 29, 18.8% | NA |
| 1:32 (n, %) | 32, 29.1% | 36, 23.4% | NA |
| 1:64 (n, %) | 14, 12.7% | 28, 18.2% | NA |
| 1:128 (n, %) | 12, 10.9% | 10, 6.5% | NA |
| ≥1:256 (n, %) | 11, 10.0% | 6, 3.9% | NA |
| Not available (n, %) | 11, 10.0% | 7, 4.5% | NA |
| Current serum RPR titer, median (IQR) | 1:32 (1:8, 1:64) | 1:8 (1:8, 1:32) | P<0.001 |
| 1:1 | 1, 0.9% | 0, 0% | NA |
| 1:2 | 2, 1.8% | 9, 5.8% | NA |
| 1:4 | 1, 0.9% | 16, 10.4% | NA |
| 1:8 | 27, 24.5% | 53, 34.4% | NA |
| 1:16 | 11, 10.0% | 30, 19.5% | NA |
| 1:32 | 27, 24.5% | 28, 18.2% | NA |
| 1:64 | 18, 16.4% | 14, 9.1% | NA |
| 1:128 | 11, 10.0% | 1, 0.6% | NA |
| ≥1:256 | 12, 10.9% | 3, 1.9% | NA |
| Serum TPPA positive (n, %) | 110, 100% | 154, 100% | NA |
| Serum FTA-ABS-IgG positive (n, %) | 110, 100% | 164, 100% | NA |
| Serum FTA-ABS-IgM positive (n, %) | 35, 38.1% | 33, 24.1% | P=0.052 |
| CSF RPR titer (positive: negative) | 90:20 | 45:109 | P<0.001 |
| 1:1 | 24, 21.8% | 19, 12.3% | NA |
| 1:2 | 24, 21.8% | 21, 13.6% | NA |
| 1:4 | 22, 20.0% | 3, 1.9% | NA |
| 1:8 | 13, 11.8% | 1, 0.6% | NA |
| 1:16 | 6, 5.5% | 0, 0% | NA |
| 1:32 | 1, 0.9% | 1, 0.6% | NA |
| CSF WBC count, median (IQR), /ul | 10 (6, 33) | 7 (5, 11) | P<0.001 |
| >5/ul (n, %) | 91, 82.7% | 125, 81.2% | P=0.746 |
| CSF protein concentration, median (IQR), mg/dl | 56.2 (43.1, 76.8) | 35.3 (26.2, 46.6) | P<0.001 |
| >45mg/dl (n, %) | 75, 68.1% | 44, 28.6% | P<0.001 |
| CSF TPPA positive (n, %) | 110, 100% | 154, 100% | NA |
| CSF FTA-ABS-IgG positive (n, %) | 110, 100% | 154, 100% | NA |
| CSF FTA-ABS-IgM positive (n, %) | 1, 0.9% | 1, 0.6% | NA |
Abbreviation: ANS=asymptomatic neurosyphilis; SNS=symptomatic neurosyphilis; RPR = rapid plasma regain; TPPA=Treponema pallidum particle agglutination; CSF=cerebrospinal fluid; WBC=white blood cells; FTA-ABS=fluorescent treponemal antibody absorption; NA=not available
Univariate and multivariate analysis for clinical and laboratory predictors of SNS patients.
| Factors | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95%CI) | P-value | OR (95%CI) | P-value | |
| Sex, male vs female | 4.556 (2.591~8.010) | P<0.001 | 2.833 (1.394~5.880) | P=0.009 |
| Age, ≥45 vs < 45, years | 3.928 (2.308~6.684) | P<0.001 | 3.611 (1.713~7.612) | P=0.001 |
| Treatment history, no vs yes | 0.357 (0.215~0.591) | P<0.001 | 0.247 (0.119~0.512) | P<0.001 |
| Pretreatment serum RPR titer | 1.246 (1.060~1.464) | P=0.008 | 0.837 (0.643~1.090) | P=0.187 |
| Current RPR titer | 1.579 (1.337~1.865) | P<0.001 | 1.373 (1.047~1.800) | P=0.022 |
| Serum FTA-ABS-IgM, + vs - | 1.734 (0.994~3.026) | P=0.053 | 0.957 (0.413~2.215) | P=0.917 |
| CSF protein concentration, mg/dl | 1.032 (1.020~1.046) | P<0.001 | 1.017 (1.002~1.033) | P=0.026 |
| CSF WBC count, /ul | 1.012 (1.004~1.021) | P=0.005 | 1.001 (0.992~1.010) | P=0.816 |
| CSF RPP, + vs - | 9.208 (5.215~16.258) | P<0.001 | 4.616 (2.185~9.752) | P<0.001 |
Abbreviation: ANS=asymptomatic neurosyphilis; SNS=symptomatic neurosyphilis; RPR = rapid plasma regain; TPPA=Treponema pallidum particle agglutination; CSF=cerebrospinal fluid; WBC=white blood cells; FTA-ABS=fluorescent treponemal antibody absorption; OR=odds ratio; CI=confidence interval;